Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir

Optimus Pharma received DCGI nod for conducting Phase III clinical trials for orally administered Molnupiravir capsules on patients with mild to moderate C-19 patients. After developing the active pharma ingredient (API) and the formulations for the product, Optimus…